Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes

By sjmartinez • May 30, 2025

Medford AJ, Velimirovic M, Gefen Y, Niemierko A, Gerratana L, Davis AA, Clifton K, Keenan J, Podany E, Hensing WL, Reduzzi C, Dai CS, Kiedrowski LA, Spring LM, Ellisen LW, Doebele RC, Cristofanilli M, Getz G, Bardia A. Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes. Breast Cancer Res Treat. 2025 May 29. doi: 10.1007/s10549-025-07710-w. Epub ahead of print. PMID: 40439821.

Tags: breast cancer, circulating tumor DNA, Genomics, Hematology/Oncology, Liquid biopsy., Publications

Related Posts

First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS <50% and ≥50% Cohorts of the EVOKE-02 Study

Reck M, Patel JD, Gray JE, Reguart N, Cobo M, Pradera JF, Felip E, Cappuzzo F, Garon EB, Neal JW, Mekan S, Safavi F, Fernando[...]

Retraction Note: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH 3rd, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R,[...]

Author Correction: Barcoded HIV-1 reveals viral persistence driven by clonal proliferation and distinct epigenetic patterns

Zhang TH, Shi Y, Komarova NL, Wodarz D, Kostelny M, Gonzales A, Abbaali I, Chen H, Bresson-Tan G, Dimapasoc M, Harvey W, Oh C, Carmona[...]